2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary
Armstrong A, Gooderham M, Warren R, Papp K, Strober B, Thaçi D, Morita A, Szepietowski J, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary. Immunotherapy 2023, 15: 963-973. PMID: 37150952, DOI: 10.2217/imt-2023-0061.Peer-Reviewed Original ResearchConceptsSevere plaque psoriasisPlaque psoriasisSide effectsNew treatmentsBasic everyday tasksStudy treatment phaseCommon side effectsMonths of treatmentSymptoms of psoriasisPsoriasis plaquesDaily pillPsoriasis treatmentAcceptable safetyClinical trialsPsoriasisTreatment phasePlaceboDeucravacitinibNasal passagesLarger studyApremilastSkin appearanceEmotional distressTreatmentPillsTreatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary
Strober B, Thaçi D, Sofen H, Kircik L, Gordon K, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp K. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary. Immunotherapy 2023, 15: 787-797. PMID: 37150956, DOI: 10.2217/imt-2023-0062.Peer-Reviewed Original ResearchConceptsSevere plaque psoriasisPlaque psoriasisSide effectsNew treatmentsBasic everyday tasksCommon side effectsMonths of treatmentUndesirable side effectsPatch of skinDaily pillPsoriasis treatmentClinical trialsPlaceboPsoriasisDeucravacitinibLarger studyTreatmentApremilastGreater improvementMore participantsSimilar ratesPillsMedical journalsParticipantsSimilar number
2019
Tofacitinib benefit‐risk profile in chronic plaque psoriasis
Strober B, Gottlieb A, Kerkhof P, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R. Tofacitinib benefit‐risk profile in chronic plaque psoriasis. British Journal Of Dermatology 2019, 180: e19-e19. DOI: 10.1111/bjd.17373.Peer-Reviewed Original ResearchBiologic treatmentSevere psoriasisPlaque psoriasisHigh doseChronic plaque psoriasisHerpes zoster infectionSevere plaque psoriasisAcceptable safety profileBenefit-risk profileNew oral drugsZoster infectionPatient yearsTofacitinib treatmentUlcerative colitisPatients' qualityRheumatoid arthritisSafety profileAppearance of skinClinical trialsOral drugsEffective treatmentSide effectsPsoriasisPatientsDrugs
2016
Treatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series
Klufas D, Wald J, Strober B. Treatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series. Pediatric Dermatology 2016, 33: 142-149. PMID: 26871417, DOI: 10.1111/pde.12782.Peer-Reviewed Original ResearchConceptsSevere pediatric psoriasisRetrospective case seriesPediatric psoriasisCase seriesSevere psoriasisSystemic therapySide effectsDisease responseSimilar side effect profilePhysician Global Assessment scaleComprehensive safety profileSmall sample sizeSingle referral centerSubjective side effectsSide effect profileSafety of treatmentMultiple treatment optionsAdverse event occurrenceComparison of efficacyGlobal Assessment ScalePaucity of dataAdult psoriasisImmunomodulating therapiesAdverse eventsReferral center
2009
Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference
Kalb R, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. Journal Of The American Academy Of Dermatology 2009, 60: 824-837. PMID: 19389524, DOI: 10.1016/j.jaad.2008.11.906.Peer-Reviewed Original ResearchConceptsTreatment of psoriasisUse of methotrexateLiver biopsyNational Psoriasis Foundation Medical BoardAppropriate patient selectionNational Psoriasis FoundationEvidence-based studiesMedical boardsMethotrexate therapyPatient selectionRheumatoid arthritisTreatment optionsHepatic fibrosisRisk factorsConsensus conferencePsoriasisSide effectsEffective drugsLast guidelinesMethotrexateValuable optionTreatmentBiopsyTask ForceReport
2005
Folate supplementation during methotrexate therapy for patients with psoriasis
Strober B, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. Journal Of The American Academy Of Dermatology 2005, 53: 652-659. PMID: 16198787, DOI: 10.1016/j.jaad.2005.06.036.Peer-Reviewed Original ResearchConceptsFolate supplementationSide effectsMethotrexate therapyFolinic acidFolic acidUse of methotrexateEfficacy of methotrexateIncidence of hepatotoxicityTreatment of psoriasisSignificant side effectsUse of folateGastrointestinal intoleranceFolate supplementsInflammatory conditionsMEDLINE searchClinical experiencePatientsMethotrexateFolate antagonistTherapySupplementationSearch termsPsoriasisEfficacyToxicity
2001
Eyelash hypertrichosis in a patient treated with topical latanoprost.
Strober B, Potash S, Grossman M. Eyelash hypertrichosis in a patient treated with topical latanoprost. Cutis 2001, 67: 109-10. PMID: 11236218.Peer-Reviewed Original ResearchConceptsTopical latanoprostSide effectsPrimary open-angle glaucomaProstaglandin F2 alpha analogueIntraocular pressure-lowering agentsCosmetic side effectsPressure-lowering agentsOpen-angle glaucomaEyelash hypertrichosisIridal pigmentationFemale patientsAlpha analogueHypertrichosisLatanoprostPatientsMolecular mechanismsGlaucoma